Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Brandon George Smaglo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8814-8004; OpenAlex author ID A5024146796. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 2, last author 0)
Trials
6 (principal investigator on 6)
Grants
0
Labs led
0
Collaborators
84
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 trial · 2017: 1 trial · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 trials · 2022: 1 paper, 1 trial · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers, 1 trial

Papers 17

  1. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Co-author DOI 10.1038/s41591-025-04043-5↗
  2. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  3. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  4. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. First author DOI 10.1038/s41467-025-63718-2↗
  5. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  6. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  7. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  8. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): resul… Co-author DOI 10.1016/s1470-2045(24)00079-2↗
  9. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  10. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  11. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Tri… Co-author DOI 10.1007/s12029-023-00930-7↗
  12. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  13. Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers15082377↗
  14. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  15. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1301↗
  16. Profile and potential of ixabepilone in the treatment of pancreatic cancer. First author DOI 10.2147/dddt.s52964↗
  17. Postresection chemotherapy for pancreatic cancer. Co-author DOI 10.1097/ppo.0b013e31827459d8↗

Trials 6

  1. A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma Principal investigator NCT07700212↗
  2. A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal… Principal investigator NCT05273554↗
  3. iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation Principal investigator NCT03608631↗
  4. Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Principal investigator NCT04940286↗
  5. Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery Principal investigator NCT02930902↗
  6. Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer Principal investigator NCT02907099↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shubham Pant · 10 shared papers, 2023–2026 · strength 1.80
  2. Robert A. Wolff · 10 shared papers, 2022–2026 · strength 1.75
  3. Matthew H. G. Katz · 8 shared papers, 2022–2026 · strength 1.36
  4. Michael James Overman · 7 shared papers, 2022–2026 · strength 1.23
  5. Anirban Maitra · 6 shared papers, 2024–2026 · strength 1.12
  6. Eugene Jon Koay · 6 shared papers, 2023–2026 · strength 1.06
  7. Ryan W. Huey · 5 shared papers, 2024–2026 · strength 0.96
  8. Rebecca Anne Snyder · 5 shared papers, 2024–2026 · strength 0.93
  9. Dan Zhao · 5 shared papers, 2024–2026 · strength 0.89
  10. Jason A. Willis · 5 shared papers, 2024–2026 · strength 0.89
  11. Ching-Wei David Tzeng · 5 shared papers, 2022–2025 · strength 0.86
  12. Naruhiko Ikoma · 5 shared papers, 2022–2026 · strength 0.86
  13. Ethan Bernard Ludmir · 5 shared papers, 2023–2026 · strength 0.85
  14. Abdelrahman M.G. Yousef · 4 shared papers, 2024–2026 · strength 0.71
  15. Mahmoud Yousef · 4 shared papers, 2024–2026 · strength 0.71
  16. Michael P. Kim · 4 shared papers, 2022–2025 · strength 0.67
  17. Saikat Chowdhury · 3 shared papers, 2024–2026 · strength 0.52
  18. Laura R. Prakash · 3 shared papers, 2022–2025 · strength 0.50
  19. Jeffrey E. Lee · 3 shared papers, 2022–2025 · strength 0.50
  20. Rishi Surana · 2 shared papers, 2023–2026 · strength 0.40
  21. Ann Marie Leen · 2 shared papers, 2024–2026 · strength 0.39
  22. Benjamin Musher · 2 shared papers, 2024–2026 · strength 0.39
  23. Haoqiang Ying · 2 shared papers, 2025–2026 · strength 0.36
  24. Huamin Wang · 2 shared papers, 2024–2025 · strength 0.35
  25. Michael S. Lee · 2 shared papers, 2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.